Controversial Hydroxychloroquine COVID-19 Study Formally Retracted
In a significant development, a controversial study promoting hydroxychloroquine, an antimalarial drug, as a COVID-19 treatment has been officially retracted. Elsevier, a Dutch academic publishing company that hosts the International Journal of Antimicrobial Agents, withdrew the study from March 2020, citing concerns about its compliance with their publishing ethics and appropriate human research conduct.
The Guardian reported that hydroxychloroquine initially sparked hope as a COVID-19 treatment when options were scarce. As nations locked down and hospitals grappled with overwhelmed ICUs and morgues, the study offered a glimmer of hope for a new, potentially effective treatment. However, scientists swiftly questioned the size and scientific rigor of the study, and follow-up research failed to reproduce its findings.
Now, the journal that first published the study, along with three of its 18 authors, have agreed to retract it. Since the study’s publication, three authors—Johan Courjon, Valérie Giordanengo, and Stéphane Honoré—have contacted the journal expressing concerns about the presentation and interpretation of its results and requesting their names be disassociated from the article. However, some other authors disagree with the retraction and contest its stated reasons.
According to Nature, the hydroxychloroquine COVID-19 study was the most cited paper on SARS-COV-2 treatments at the time of its publication. Its retraction underscores the importance of robust scientific scrutiny and adherence to ethical standards, particularly when studies generate significant attention and influence.
